3,4-Dehydro Cilostazol (OPC-13015) is the bioactive metabolite of cilostazol (CLZ). 3,4-Dehydro Cilostazol may be utilized in pharmacokinetic studies.

Physicochemical Properties

Molecular Formula	C20H25N5O2
Molecular Weight	367.44
Exact Mass	367.201
CAS #	73963-62-9
PubChem CID	10021885
Appearance	Off-white to gray solid powder
Density	1.342g/cm3
Boiling Point	675.937ºC at 760 mmHg
Melting Point	179-180ºC
Flash Point	362.594ºC
Index of Refraction	1.676
LogP	3.421
Hydrogen Bond Donor Count	1
Hydrogen Bond Acceptor Count	5
Rotatable Bond Count	7
Heavy Atom Count	27
Complexity	523
Defined Atom Stereocenter Count	0
InChi Key	GHALECSGOJQOHW-UHFFFAOYSA-N
InChi Code	InChI=1S/C20H25N5O2/c26-20-12-9-15-14-17(10-11-18(15)21-20)27-13-5-4-8-19-22-23-24-25(19)16-6-2-1-3-7-16/h9-12,14,16H,1-8,13H2,(H,21,26)
Chemical Name	6-[4-(1-cyclohexyltetrazol-5-yl)butoxy]-1H-quinolin-2-one
HS Tariff Code	2934.99.9001
Storage	Powder-20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Shipping Condition	Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)

Biological Activity

ln Vivo	3,4-Dehydro Cilostazol (OPC-13015; Oral; 1 mg/kg GLZ and 10 mg/kg CLZ) exhibits an AUC0-24 of 4.69 μg·h/ml, a Cmax of 1.39 μM, and a T1/2 of 3.94 hours. After oral administration of GLZ at a dose of 1 mg/kg and CLZ at a dose of 10 mg/kg, the plasma concentration time profiles of GLZ, CLZ, and its active metabolite DCLZ can be traced for up to 24 hours, 12 hours, and 12 hours, respectively[1].
Animal Protocol	Animal/Disease Models: Male Wistar rats weighing 200 g[1] Doses: 1 mg/kg Glipizide (GLZ) and 10 mg/kg Cilostazol (CLZ) (pharmacokinetic/PK Analysis) Route of Administration: Oral Experimental Results: Had a T1/2 of 3.94 hrs (hours), a Cmax of 1.39 μM and an AUC0-24 of 4.69 μg·h/ml.
References	[1]. Liquid Chromatography - Tandem Mass Spectrometry for the Simultaneous Quantitation of Glipizide, Cilostazol and Its Active Metabolite 3, 4-dehydro-cilostazol in Rat Plasma: Application for a Pharmacokinetic Study. Arzneimi.
Additional Infomation	3,4-Dehydrocilostazol is a member of quinolines.

Solubility Data

Solubility (In Vitro)

DMSO: 5 mg/mL (13.61 mM)

Solubility (In Vivo)

Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples. Injection Formulations (e.g. IP/IV/IM/SC) Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] *Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. Injection Formulation 5: 2-Hydroxypropyl-β-cyclodextrin : Saline = 50 : 50 (i.e. 500 μL 2-Hydroxypropyl-β-cyclodextrin → 500 μL Saline) Injection Formulation 6: DMSO : PEG300 : castor oil : Saline = 5 : 10 : 20 : 65 (i.e. 50 μL DMSO → 100 μLPEG300 → 200 μL castor oil → 650 μL Saline) Injection Formulation 7: Ethanol : Cremophor : Saline = 10： 10 : 80 (i.e. 100 μL Ethanol → 100 μL Cremophor → 800 μL Saline) Injection Formulation 8: Dissolve in Cremophor/Ethanol (50 : 50), then diluted by Saline Injection Formulation 9: EtOH : Corn oil = 10 : 90 (i.e. 100 μL EtOH → 900 μL Corn oil) Injection Formulation 10: EtOH : PEG300：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL EtOH → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Oral Formulations Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). Oral Formulation 3: Dissolved in PEG400 Oral Formulation 4: Suspend in 0.2% Carboxymethyl cellulose Oral Formulation 5: Dissolve in 0.25% Tween 80 and 0.5% Carboxymethyl cellulose Oral Formulation 6: Mixing with food powders Note: Please be aware that the above formulations are for reference only. InvivoChem strongly recommends customers to read literature methods/protocols carefully before determining which formulation you should use for in vivo studies, as different compounds have different solubility properties and have to be formulated differently.  (Please use freshly prepared in vivo formulations for optimal results.)

Preparing Stock Solutions		1 mg	5 mg	10 mg
	1 mM	2.7215 mL	13.6077 mL	27.2153 mL
	5 mM	0.5443 mL	2.7215 mL	5.4431 mL
	10 mM	0.2722 mL	1.3608 mL	2.7215 mL

*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.